Life Sciences Deal-Making Gets Creative, Aims At Early Stages Amid COVID-19
By Jeff Stoll and Kristin Pothier
Life sciences companies remain unabated when it comes to creatively making deals during the COVID-19 pandemic, particularly among those targeting biopharma companies with early-stage assets.
In the KPMG 2021 Healthcare & Life Sciences Investment Outlook, we tallied 1,138 acquisitions, licensing, and R&D deals announced in 2020, an increase from 634 in 2019. In 2020, we saw 121 company acquisitions globally versus 79 in 2019.
The dollar value of the deals was smaller than in 2019, but the volume of deals shows that investors don’t want to miss early-stage opportunities.
Our survey of life sciences executives and investors found that 71% were interested in targeting early-stage assets, compared with 39% who favored late-stage assets with greater certainty of near-term revenue. Only 29% were interested in significantly sized acquisitions/mergers and 23% were interest
What s going on, southeast Wisconsin spring 2021: entertainment jsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jsonline.com Daily Mail and Mail on Sunday newspapers.
3 Strategies To Address The Biggest Concerns Facing Generic Drug Makers
By Roger van den Heuvel, Mary Rollman, and Jeff Stoll, KPMG
Generic drugs, which account for 90% of the prescriptions filled in the U.S., have been a constraint on pharmaceutical inflation for decades, with many payers touting their “drug trend” a measure of spending growth of pharmaceutical drugs. Generic drug sales have grown 5.7% annually, from 2014 to 2019, and additional patent expirations could sustain 5.4% generic drug growth to $497 billion by 2025.
Amid this opportunity for generic drug makers to capitalize on patent expiration, they’re facing struggles around pricing power. COVID-19 also exposed the fragility of supply chains that were built with economic efficiency rather than resiliency in mind.